Meinian Onehealth(SZ:002044) Zheng Quan Zhi Xing·2025-07-11 13:13Core Viewpoint - The independent directors of Meinian Onehealth Healthcare Holdings Co., Ltd. have approved a series of proposals regarding the acquisition of equity stakes in multiple companies through a share issuance, which is expected to enhance the company's business structure and profitability [1][2][3]. Group 1: Approval of Proposals - The independent directors have reviewed and approved the proposal for the company to issue shares for asset acquisition, confirming compliance with relevant laws and regulations [1]. - The transaction plan for issuing shares to purchase assets and related party transactions has been deemed reasonable and operable, benefiting the company's business structure and shareholder interests [2]. - The independent directors have also approved the draft report related to the share issuance for asset acquisition, affirming its compliance with legal requirements [2]. Group 2: Transaction Characteristics - The transaction involves acquiring stakes in 11 companies, including Hengyang Meinian Health Checkup Center Co., Ltd., and minority stakes in 5 subsidiaries, including Zhengzhou Meijian Health Management Co., Ltd. [1]. - The transaction is classified as a related party transaction due to the involvement of a company controlled by the actual controller of Meinian [3]. - It has been confirmed that the transaction does not constitute a major asset restructuring as the assets involved do not exceed 50% of the company's relevant financial metrics [4]. Group 3: Compliance and Procedures - The independent directors have confirmed that the transaction adheres to the regulatory requirements for major asset restructuring and does not involve any recent changes in control [4][5]. - The company has fulfilled all necessary legal procedures and submitted valid legal documents for the transaction [7]. - The evaluation agency selected for the transaction has been deemed independent, and the valuation methods used are considered reasonable and fair [7][9]. Group 4: Financial Aspects - The total transaction price for the equity stakes is approximately 427.78 million yuan [9]. - The company has conducted an analysis of the impact of the transaction on immediate returns and has proposed measures to mitigate any potential dilution of returns [8]. Group 5: Authorization and Future Steps - The board of directors has requested authorization from the shareholders' meeting to handle all matters related to the transaction, including adjustments to the transaction plan and execution of necessary agreements [10].